Is GI’s biggest revenue engine at risk?

Advertisement

Screening colonoscopy has anchored the economics of gastroenterology practices and the surgery centers they own for decades, with colonoscopies accounting for 13.4% of all ASC procedure volume nationally.

But noninvasive alternatives are gaining ground. Guardant Health performed about 66,000 Shield blood tests in the second quarter of 2026, up from about 16,000 a year earlier, and Abbott launched Freenome’s SimpleScreen CRC, the second FDA-approved blood test for average-risk screening, on Sept. 30.

Dinesh Madhok, MD, CEO of Jacksonville, Fla.-based Borland Groover, has watched GI’s ASC model take shape from inside one of Florida’s largest independent GI groups. Borland Groover has opened four surgery centers in the last five years, Dr. Madhok told Becker’s, and the group focuses on ensuring demand before expanding facilities. 

Yet Dr. Madhok believes the core of that demand is starting to give way, and not only for independent practices.

“I would say this is not just independent GI groups. I would say for all GI groups,” he said. “I know this has been said for the last 15, 20 years, but I really do think we’re at the cusp where a lot of the GI group screening colonoscopy is really your bread and butter kind of thing. It’s the engine of your ASCs.”

In January, Dr. Madhok told Becker’s that “colonoscopy is still the only procedure that can both find and remove polyps.” Asked now about the biggest challenge facing GI groups over the next five years, he pointed to the tests competing with it.

“I think with a lot of noninvasive testing that is now available, whether it’s Cologuard or the others doing RNA-based tests or blood tests that are coming out for screening…they’re always getting better, right?” he said. “As technology keeps getting better, these tests are going to keep getting better, where their cancer detection rate and large polyp detection rate is going to keep getting better.”

“So I think at some point…the screening colonoscopy as a business is going to keep diminishing,” Dr. Madhok continued. 

Abnormal blood test results can still send patients to colonoscopy, but that follow-up volume from screening tests is not guaranteed. In a UCLA study of 6,068 patients who received the Shield test, only 56% of those with abnormal results ever had a colonoscopy. Blood tests still trail colonoscopy on precancer detection. SimpleScreen detected 81.1% of colorectal cancers but only 13.7% of advanced precancerous lesions in its pivotal trial.

The pressure on volume is arriving alongside pressure on price. CMS’ final 2027 outpatient rule cuts Medicare’s ASC payment for colonoscopy with biopsy and colonoscopy with lesion removal by 1% each starting Jan. 1. Medicare paid an estimated $526 million in ASCs for those two procedures in 2026.

Borland Groover is already looking past the procedure.

“I think as any group thinking out five or 10 years, we have to look at other avenues where we can grow,” Dr. Madhok said. “Fatty liver is becoming a big problem, and we’re sort of focusing on that somewhat.”

Fatty liver is not the only area under consideration.

“Nutrition is an issue, and we’re pivoting to that or the microbiome,” he said. “We’re trying to figure out what to do with that so far.”

Dr. Madhok sees the group’s history as its best preparation for the shift.

“The good thing about our group has been — and we’ve been successful over 35 years — is that we’ve been good at pivoting when one thing goes away,” he said. “There’s always an opportunity to do something else.”

Borland Groover’s ownership structure is part of that equation.

“We are a physician-owned company, and we plan to stay physician-owned,” Dr. Madhok said. “We have a large number of docs who are very involved in our group and want to participate in committees and decision making, and that really has led, I think, to more options that have opened up for us.”

Advertisement

Next Up in GI & Endoscopy

Advertisement